Cargando…

Simultaneous screening for COVID-19 and tuberculosis, India

OBJECTIVE: To evaluate the implementation of new operational workflows for simultaneous screening of coronavirus disease 2019 (COVID-19) and tuberculosis at four high-volume COVID-19 testing centres located in tertiary hospitals in Mumbai, India. METHODS: Each centre already offering antigen-detecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Duppala, Keertana, Sen, Rajashree, Shenai, Shubhada, Gomare, Mangala, Shah, Daksha, Tipre, Pranita, Joshi, Madhav, Chowdhury, Jayeeta, Chadha, Sarabjit S, Sarin, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Health Organization 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300779/
https://www.ncbi.nlm.nih.gov/pubmed/37397177
http://dx.doi.org/10.2471/BLT.22.288960
_version_ 1785064656883154944
author Duppala, Keertana
Sen, Rajashree
Shenai, Shubhada
Gomare, Mangala
Shah, Daksha
Tipre, Pranita
Joshi, Madhav
Chowdhury, Jayeeta
Chadha, Sarabjit S
Sarin, Sanjay
author_facet Duppala, Keertana
Sen, Rajashree
Shenai, Shubhada
Gomare, Mangala
Shah, Daksha
Tipre, Pranita
Joshi, Madhav
Chowdhury, Jayeeta
Chadha, Sarabjit S
Sarin, Sanjay
author_sort Duppala, Keertana
collection PubMed
description OBJECTIVE: To evaluate the implementation of new operational workflows for simultaneous screening of coronavirus disease 2019 (COVID-19) and tuberculosis at four high-volume COVID-19 testing centres located in tertiary hospitals in Mumbai, India. METHODS: Each centre already offering antigen-detecting rapid diagnostic tests were equipped with a rapid molecular testing platform for COVID-19 and tuberculosis, sufficient laboratory staff, and reagents and consumables for screening. Using a verbal tuberculosis questionnaire, a patient follow-up agent screened individuals visiting the COVID-19 testing centres. Presumptive tuberculosis patients were asked to provide sputum samples for rapid molecular testing. Subsequently, we reversed our operational workflow to also screen patients visiting tuberculosis outpatient departments for COVID-19, using rapid diagnostic tests. RESULTS: From March to December 2021, we screened 14 588 presumptive COVID-19 patients for tuberculosis, of whom 475 (3.3%) were identified as having presumptive tuberculosis. Of these, 288 (60.6%) were tested and 32 individuals (11.1%) were identified as tuberculosis positive (219 cases per 100 000 individuals screened). Of the tuberculosis-positive individuals, three had rifampicin-resistant tuberculosis. Among the remaining 187 presumptive tuberculosis cases not tested, 174 reported no symptoms at follow-up and 13 individuals either refused testing or could not be traced. Of the 671 presumptive tuberculosis cases screened for COVID-19, 17 (2.5%) were positive by antigen rapid diagnostic tests, and five (0.7%) who tested negative, later tested positive on the molecular testing platform (2483 COVID-19 cases per 100 000 individuals screened). CONCLUSION: Simultaneous screening for COVID-19 and tuberculosis in India is operationally feasible and can improve real-time on-site detection of COVID-19 and tuberculosis.
format Online
Article
Text
id pubmed-10300779
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher World Health Organization
record_format MEDLINE/PubMed
spelling pubmed-103007792023-07-01 Simultaneous screening for COVID-19 and tuberculosis, India Duppala, Keertana Sen, Rajashree Shenai, Shubhada Gomare, Mangala Shah, Daksha Tipre, Pranita Joshi, Madhav Chowdhury, Jayeeta Chadha, Sarabjit S Sarin, Sanjay Bull World Health Organ Research OBJECTIVE: To evaluate the implementation of new operational workflows for simultaneous screening of coronavirus disease 2019 (COVID-19) and tuberculosis at four high-volume COVID-19 testing centres located in tertiary hospitals in Mumbai, India. METHODS: Each centre already offering antigen-detecting rapid diagnostic tests were equipped with a rapid molecular testing platform for COVID-19 and tuberculosis, sufficient laboratory staff, and reagents and consumables for screening. Using a verbal tuberculosis questionnaire, a patient follow-up agent screened individuals visiting the COVID-19 testing centres. Presumptive tuberculosis patients were asked to provide sputum samples for rapid molecular testing. Subsequently, we reversed our operational workflow to also screen patients visiting tuberculosis outpatient departments for COVID-19, using rapid diagnostic tests. RESULTS: From March to December 2021, we screened 14 588 presumptive COVID-19 patients for tuberculosis, of whom 475 (3.3%) were identified as having presumptive tuberculosis. Of these, 288 (60.6%) were tested and 32 individuals (11.1%) were identified as tuberculosis positive (219 cases per 100 000 individuals screened). Of the tuberculosis-positive individuals, three had rifampicin-resistant tuberculosis. Among the remaining 187 presumptive tuberculosis cases not tested, 174 reported no symptoms at follow-up and 13 individuals either refused testing or could not be traced. Of the 671 presumptive tuberculosis cases screened for COVID-19, 17 (2.5%) were positive by antigen rapid diagnostic tests, and five (0.7%) who tested negative, later tested positive on the molecular testing platform (2483 COVID-19 cases per 100 000 individuals screened). CONCLUSION: Simultaneous screening for COVID-19 and tuberculosis in India is operationally feasible and can improve real-time on-site detection of COVID-19 and tuberculosis. World Health Organization 2023-07-01 2023-05-18 /pmc/articles/PMC10300779/ /pubmed/37397177 http://dx.doi.org/10.2471/BLT.22.288960 Text en (c) 2023 The authors; licensee World Health Organization. https://creativecommons.org/licenses/by/3.0/igo/This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (http://creativecommons.org/licenses/by/3.0/igo/legalcode (https://creativecommons.org/licenses/by/3.0/igo/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.
spellingShingle Research
Duppala, Keertana
Sen, Rajashree
Shenai, Shubhada
Gomare, Mangala
Shah, Daksha
Tipre, Pranita
Joshi, Madhav
Chowdhury, Jayeeta
Chadha, Sarabjit S
Sarin, Sanjay
Simultaneous screening for COVID-19 and tuberculosis, India
title Simultaneous screening for COVID-19 and tuberculosis, India
title_full Simultaneous screening for COVID-19 and tuberculosis, India
title_fullStr Simultaneous screening for COVID-19 and tuberculosis, India
title_full_unstemmed Simultaneous screening for COVID-19 and tuberculosis, India
title_short Simultaneous screening for COVID-19 and tuberculosis, India
title_sort simultaneous screening for covid-19 and tuberculosis, india
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300779/
https://www.ncbi.nlm.nih.gov/pubmed/37397177
http://dx.doi.org/10.2471/BLT.22.288960
work_keys_str_mv AT duppalakeertana simultaneousscreeningforcovid19andtuberculosisindia
AT senrajashree simultaneousscreeningforcovid19andtuberculosisindia
AT shenaishubhada simultaneousscreeningforcovid19andtuberculosisindia
AT gomaremangala simultaneousscreeningforcovid19andtuberculosisindia
AT shahdaksha simultaneousscreeningforcovid19andtuberculosisindia
AT tiprepranita simultaneousscreeningforcovid19andtuberculosisindia
AT joshimadhav simultaneousscreeningforcovid19andtuberculosisindia
AT chowdhuryjayeeta simultaneousscreeningforcovid19andtuberculosisindia
AT chadhasarabjits simultaneousscreeningforcovid19andtuberculosisindia
AT sarinsanjay simultaneousscreeningforcovid19andtuberculosisindia